MAX Chat
IGC Pharma, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 52.65 | -100% | -5.79 | -100% |
| P/S |
|
17.5 | 4.03 | 333.93% |
|
|
| P/BV |
|
3.21 | 10.87 | -70.42% |
|
|
| P/FCF |
|
0 | 39.64 | -100% |
|
|
| Ev/Ebitda |
|
-2.48 | 16.1 | -115.37% |
|
|
| Ev/S |
|
16.86 | 4.35 | 287.54% |
|
|
| Ev/FCF |
|
-3.97 | 52.31 | -107.59% |
|
|
| E/P |
|
0 | 0.2095 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-681.12 | 19.07 | -3670.73% | -1436.37 | -52.58% |
| ROE |
|
-116.95 | -83.32 | 40.36% |
|
|
| ROA |
|
-96.01 | 6.38 | -1605.19% |
|
|
| ROIC |
|
0 | 15.06 | -100% |
|
|
| ROS |
|
-966.54 | 9.34 | -10453.54% |
|
|
| ROCE |
|
-133.83 | 84.76 | -257.89% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0377 | 1.01 | -103.74% | -0.0448 | -16.02% |
| Nеt Debt/Ebitda |
|
0.0931 | 1.4 | -93.34% |
|
|
| Debt/Ratio |
|
0.0348 | 0.2742 | -87.29% |
|
|
| Debt/Equity |
|
0.3525 | 15.68 | -97.75% |
|
|
| Debt/Net Income |
|
-0.0265 | 6.8 | -100.39% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.28 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 6.75 | -100% | ||
| DSI |
|
0 | 0.7413 | -100% |
|
|
| Average dividend growth |
|
0 | -4.1 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.33 | -100% |
|
|
| Average percentage for payments |
|
0 | 44.08 | -100% |
|
|
| Difference from average difference in sector |
|
-1.28 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-67.2 | 12.47 | -638.89% | ||
| Growth impulse Ebitda in 5 years |
|
55.27 | -86.3 | -164.04% | ||
| Growth impulse Net Income in 5 years |
|
52.94 | -75.86 | -169.79% | ||
| Growth impulse FCF in 5 years |
|
-56.38 | -79.28 | -28.88% | ||
| Growth impulse EPS in 5 years |
|
2.05 | 4.34 | -52.76% |
IP Score
3.43/10
